Venus Medtech (Hangzhou), Inc. Class H

As of December 31, 2025, Venus Medtech (Hangzhou), Inc. Class H carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 825.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Venus Medtech (Hangzhou), Inc. Class H's next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, Venus Medtech (Hangzhou), Inc. Class H has 441.01M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Venus Medtech (Hangzhou), Inc. Class H maintains a current ratio of 2.77, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Venus Medtech (Hangzhou), Inc. Class H's stock has declined approximately 59.92% over the past 52 weeks. The 50-day moving average sits at 1.11, while the 200-day moving average is 1.74.

As of December 31, 2025, Venus Medtech (Hangzhou), Inc. Class H holds 293.54M in cash and equivalents against 69.14M in total debt, resulting in a net debt position of -170.64M. Total book value stands at 1.96B, with working capital of 474.53M providing operational flexibility.